How does this company make money?
The company earns money each time a hospital buyer or specialty pharmacy purchases a patented drug like DARZALEX, with revenue counted at the point of shipment. It also sells medical devices — including OMNYPULSE systems sold through its own sales representatives — and ACUVUE contact lenses sold through eye care professionals. On top of that, it collects royalty payments when other companies use its patents, as well as milestone payments tied to partnership agreements.
What makes this company hard to replace?
A patient already receiving DARZALEX cannot simply swap to a different multiple myeloma treatment overnight — switching requires careful dose adjustments and safety monitoring over a 3 to 6 month transition period. For hospital buyers using devices like OMNYPULSE, physicians have been trained on specific ablation techniques that do not transfer to a competitor's equipment. Any company trying to sell a biosimilar copy of DARZALEX faces 5 to 8 years of analytical and clinical studies just to prove it matches the original closely enough for FDA approval.
What limits this company?
Each bioreactor takes 14 to 21 days to complete one batch, and no new bioreactor can ship a single commercial batch until it passes its own FDA validation. That validation process is set by regulatory timelines, not by money — writing a bigger cheque does not make it go faster. The number of validated reactors at approved sites is therefore the hard ceiling on how much DARZALEX can exist at any given time.
What does this company depend on?
The company cannot operate without CHO cell lines that produce daratumumab, FDA manufacturing licences for its New Brunswick and international biologics facilities, cold-chain logistics networks that keep the drug between 2 and 8°C during shipping, specialised single-use bioreactor systems from suppliers like Cytiva, and active pharmaceutical ingredients sourced from validated chemical manufacturers for its small molecule drugs.
Who depends on this company?
Multiple myeloma patients at cancer centres receive DARZALEX infusions every 3 to 4 weeks — if supply stopped, their treatment would be directly interrupted. Hospital pharmacy buyers would have to scramble to find alternative multiple myeloma treatments for patients already on a schedule. Medicare and commercial insurers that list DARZALEX as a standard covered therapy would need to rewrite their coverage policies.
How does this company scale?
Once a drug like DARZALEX is approved, its manufacturing process can be copied into additional bioreactors as long as each new reactor completes FDA validation first — so production can grow, just slowly. What cannot be sped up at all is the development of new drugs: FDA Phase I through Phase III trials require patients to be enrolled one stage at a time and watched for safety over 8 to 12 years, and no amount of money compresses that clock.
What external forces can significantly affect this company?
The Inflation Reduction Act gives Medicare the authority to directly cap the price of established drugs like DARZALEX once they have been on the market for nine years. Revenue from European and Japanese sales of products like TREMFYA shrinks or grows depending on how those currencies move against the US dollar. An ageing population means more cancer patients, but it also means government and private insurers are pushing harder to control what they pay for cancer drugs.
Where is this company structurally vulnerable?
If an FDA inspection finds a quality-system problem at any one of the validated biologics facilities, the agency can suspend that site's licence. Because the licence covers everything made at that address — not just DARZALEX — a single compliance failure at one building could legally stop every product manufactured there from reaching patients.
CompanyGraph